ImpediMed Limited (ASX: IPD), the global leader in the design and manufacture of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of tissue composition and fluid status, announces that Dennis Schlaht, senior vice president, R&D and Technology, received the 2018 Lymphatic Education & Research Network (LE&RN) Advocate Award at the annual 5K Run/Walk to Fight Lymphedema & Lymphatic Diseases. Schlaht was recognized for his contributions in raising awareness and funding for diseases that affect over 10 million Americans and up to 170 million worldwide.

“As a result of the commitment of people like Dennis Schlaht, this movement has gained significant momentum over the past few years,” says William Repicci, president and CEO, LE&RN. “An early corporate supporter and active participant in LE&RN and its events, Dennis has left a lasting impression on Run/Walk participants. His involvement is so valuable for patients who often feel isolated as they struggle with these diseases. Extraordinary individuals like Dennis are so deserving of the honors presented to them.”

LE&RN is an internationally recognized non-profit organization founded in 1998 to fight lymphatic diseases and lymphedema through education, research and advocacy. LE&RN spokesperson actor Kathy Bates hosted a cocktail reception for top fund raisers in conjunction with the event.

Schlaht says, “It is so gratifying to witness our progress and see our dreams becoming reality. It has been my honor to support the organization and shine a light on these diseases which have been largely ignored or misdiagnosed. At ImpediMed, their struggles are part of the passion that fuels our personal and professional commitment. We will continue to build public awareness, provide education and engage the healthcare community in changing the lives of all those who face the challenges of these diseases.”

About ImpediMed

Founded and headquartered in Brisbane, Australia, with U.S. and European operations, ImpediMed is the world leader in the design and manufacture of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of tissue composition and fluid status. ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO® for multiple indications, including heart failure and lymphoedema, sold in select markets globally. Visit www.impedimed.com.

Media:For ImpediMedLaura Carabello, 201-641-1911 x12lcarabello@cpronline.com

Impedimed (ASX:IPD)
Gráfico Histórico do Ativo
De Dez 2024 até Jan 2025 Click aqui para mais gráficos Impedimed.
Impedimed (ASX:IPD)
Gráfico Histórico do Ativo
De Jan 2024 até Jan 2025 Click aqui para mais gráficos Impedimed.